Good Morning Ariellla:
Monday October 5, 7:45 am Eastern Time
Company Press Release
SOURCE: Pharmos Corporation
Experimental Treatment for Severe Head Trauma
Pharmos Corporation will announce the results of a Phase II clinical trial that evaluated dexanabinol, a marijuana analog, in treating severe head trauma. A teleconference will be held shortly
after the announcement.
WHO: Dr. Nachshon Knoller, MD, principal investigator
DATE: October 7, 1998
TIME: 10:00 a.m. PT
If you would like to participate in the teleconference, please call Gwyn Crosson at 732-603-3526 or Lev Janashvili at 212-583-2761 to obtain the dial-in number for the teleconference or call
Barbara Peck in the press room at 206-505-6476 to attend in person.
Head Trauma Factoid
There is currently no approved drug for the treatment of head trauma.
Head trauma is the number one cause of death for people aged 18-30.
In the U.S. alone, more than 373,000 people are hospitalized for severe
head injuries each year, and more than 99,000 of these individuals
sustain moderate to severe brain injuries that result in lifelong
disabling conditions.
SOURCE: Pharmos Corporation |
